Xbrane Biopharma

Executive Summary

Xbrane Biopharma is a Swedish biopharmaceutical company focused on developing and manufacturing biosimilars to increase patient access to costly biological drugs. Founded in 2010 and based in Stockholm, the company leverages proprietary technology to produce complex protein-based therapeutics. Its mission is to address the high cost of biologics used in oncology, autoimmune diseases, and ophthalmology. Xbrane’s lead candidate targets a blockbuster biologic with a growing market. The company has a robust pipeline and collaborates with global partners for clinical development and commercialization. By focusing on high-barrier-to-entry biosimilars, Xbrane aims to capture significant market share upon approval. The company is privately held and has not yet disclosed its valuation or funding history. With a strong scientific foundation and strategic positioning, Xbrane is poised to become a key player in the global biosimilar market.

Upcoming Catalysts (preview)

• Q1 2026EU marketing authorization decision for lead biosimilar candidate75% success
• Q2 2026Partnership agreement with a major pharmaceutical company for commercial launch70% success
• Q4 2026Phase 3 clinical trial results for second pipeline asset60% success